Clinical Trial: NCT06459193
Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Minia University |
| Information Provided By: | Minia University |
| Last Update Posted: | 2025-03-30 |
Study Overview
Brief Summary
This proof-of-concept study evaluated the effect of Trimetazidine on the incidence of paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Official Title
Evaluation of Trimetazidine in Alleviating Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients
Conditions
Peripheral Neuropathy Due to Chemotherapy
Intervention / Treatment
- Drug: Trimetazidine
- Drug: Placebo
Other Study ID Numbers
- 2301006
Start Date (Actual)
2024-06-23
Primary Completion Date (Actual)
2025-01-28
Study Completion Date (Actual)
2025-03-27
Enrollment (Actual)
60
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Minia University |
| Information Provided By: | Minia University |
| Last Update Posted: | 2025-03-30 |
Study Overview
Brief Summary
This proof-of-concept study evaluated the effect of Trimetazidine on the incidence of paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Official Title
Evaluation of Trimetazidine in Alleviating Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients
Conditions
Peripheral Neuropathy Due to Chemotherapy
Intervention / Treatment
- Drug: Trimetazidine
- Drug: Placebo
Other Study ID Numbers
- 2301006
Start Date (Actual)
2024-06-23
Primary Completion Date (Actual)
2025-01-28
Study Completion Date (Actual)
2025-03-27
Enrollment (Actual)
60
Study Type
Interventional
Phase
Phase 1, Phase 2